Categories: News

Halberd Entering the Medical Metaverse

Jackson Center, Pennsylvania–(Newsfile Corp. – April 11, 2022) – Halberd Corporation (OTC PINK: HALB) announces plans to enter the Metaverse by the creation of non-fungible tokens (NFT’s) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc.

Halberd is currently in negotiations to engage a team of experts in Metaverse with expertise in non-fungible tokens (NFT’s) who can identify growth opportunities by monitoring the evolving marketplace, setting category strategy, and managing key partners essential to our company’s growth in this emerging sector.

Halberd is planning a series of non-fungible tokens (NFT’s) in the future for its intellectual property rights, including, but not limited to, patents, patents pending, trade secrets, etc. Furthermore, shareholders and non-shareholders will be able to purchase these NTF’s through a personalized electronic wallet independently on the NFT market(s). The owners will have tokenized rights to the specific intellectual properties as determined by the company.

William A. Hartman, Halberd’s Chairman, President & CEO explained, “This will maximize and accelerate liquidity for our shareholders. This will be part of our full-service program, which will include experts furnishing full guidance to shareholders in this process, easily at zero cost to the shareholders. Each shareholder will own, not only common shares in HALB, but, separately, will also own intellectual property rights in the form of these tokens. Shareholders will not just own stock, but each shareholder will also own a fundamental part of the company, enjoying at least two separate sources of liquidity. Halberd now owns the trademark Medical MetaverseTM.”

To get the latest news on Halberd’s exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC-PINK: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/120011

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

53 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

54 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

57 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

57 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

57 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

57 minutes ago